BioTelemetry - BEAT Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$4.08
▼ -0.07 (-1.69%)
Get New BioTelemetry Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BEAT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BEAT

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 2 analysts offering 12 month price targets for BioTelemetry in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $4.08.

This chart shows the closing price for BEAT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 investment analysts is to buy stock in BioTelemetry. This rating has held steady since December 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 5 hold ratings
  • 0 sell ratings
4/13/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 0 sell ratings
7/12/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
10/10/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/8/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/8/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/7/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/5/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/5/2022

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/25/2022Dawson JamesInitiated CoverageBuyN/A
12/20/2021BenchmarkInitiated CoverageBuyN/A
12/29/2020Truist FinancialDowngradeBuy ➝ Hold$58.00 ➝ $72.00N/A
12/21/2020Colliers SecuritiesDowngradeBuy ➝ NeutralLow
12/18/2020SidotiDowngradeBuy ➝ NeutralLow
12/18/2020Needham & Company LLCDowngradeBuy ➝ Hold$52.00High
12/3/2020BenchmarkBoost TargetPositive ➝ Buy$52.00 ➝ $64.00Medium
9/11/2020Needham & Company LLCInitiated CoverageBuy$52.00High
9/1/2020Robert W. BairdInitiated CoverageNeutral$43.00Medium
7/8/2020SunTrust BanksReiterated RatingBuy$58.00Medium
3/19/2020BenchmarkLower TargetBuy$82.00 ➝ $55.00High
2/27/2020SidotiLower TargetBuy$81.00 ➝ $75.00High
1/7/2020SunTrust BanksInitiated CoverageBuy$58.00High
11/6/2019Lake Street CapitalReiterated RatingBuy$90.00 ➝ $80.00High
8/2/2019Raymond JamesDowngradeOutperform ➝ Market PerformHigh
7/31/2019Lake Street CapitalSet TargetBuy$90.00High
7/31/2019SidotiLower TargetBuy$95.00 ➝ $87.00Medium
7/31/2019Raymond JamesLower TargetOutperform$62.00 ➝ $54.00High
4/26/2019Dougherty & CoReiterated RatingBuy ➝ Buy$81.00 ➝ $75.00Low
4/2/2019BenchmarkSet TargetBuy$82.00Low
2/22/2019Lake Street CapitalSet TargetBuy$90.00High
2/5/2019SidotiSet TargetBuy$95.00Medium
10/31/2018Raymond JamesLower TargetOutperform ➝ Outperform$66.00 ➝ $64.00High
9/14/2018Raymond JamesBoost TargetOutperform$57.00 ➝ $66.00Medium
8/31/2018SunTrust BanksBoost TargetBuy$67.00High
7/26/2018Lake Street CapitalBoost TargetBuy$50.00 ➝ $90.00High
6/20/2018BenchmarkBoost TargetBuy$46.00 ➝ $54.00Medium
4/26/2018BenchmarkReiterated RatingBuy ➝ Buy$44.00 ➝ $46.00High
2/23/2018Dougherty & CoReiterated RatingBuy ➝ Buy$40.00 ➝ $41.00Low
11/8/2017Dougherty & CoReiterated RatingBuy$40.00N/A
10/26/2017Raymond JamesInitiated CoverageOutperform$37.00N/A
10/23/2017SunTrust BanksInitiated CoverageBuy$41.00N/A
(Data available from 10/5/2017 forward)

News Sentiment Rating

0.35 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/9/2022
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/8/2022
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
5/8/2022
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/7/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/7/2022
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/6/2022
  • 0 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/5/2022
  • 2 very positive mentions
  • 15 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
10/5/2022

Current Sentiment

  • 2 very positive mentions
  • 15 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
BioTelemetry logo
BioTelemetry, Inc., a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core laboratory services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. It operates in two segments, Healthcare and Research. The Healthcare segment focuses on the remote cardiac monitoring to identify cardiac arrhythmias or heart rhythm disorders. This segment offers mobile cardiac telemetry services; and event monitoring services, which enable physicians to prescribe wireless event, digital loop event, memory loop event, memory loop event, and non-loop event monitors. It also provides traditional and extended Holter, pacemaker, international normalized ratio, implantable loop recorder, and other implantable cardiac device monitoring services. It serves cardiologists, electrophysiologists, neurologists, and primary care physicians. The Research segment offers laboratory services, such as cardiac monitoring, imaging, scientific consulting, and data management services for drug and medical device trials. Its centralized services comprise electrocardiogram, Holter monitoring, ambulatory blood pressure monitoring, echocardiography, multigated acquisition scan, imaging, protocol development, expert reporting, and statistical analysis. It also provides support services, such as project coordination, setup and management, equipment rental, data transfer, processing, analysis, and 24/7 customer support and site training. The company also focuses on manufacturing, testing, and marketing of cardiac devices and blood glucose monitoring devices, as well as offers contract manufacturing services. BioTelemetry, Inc. was founded in 1994 and is headquartered in Malvern, Pennsylvania.
Read More

Today's Range

Now: $4.08
Low: $3.76
High: $4.31

50 Day Range

MA: $71.92
Low: $71.46
High: $72.27

52 Week Range

Now: $4.08
Low: $27.35
High: $73.10

Volume

1,415,825 shs

Average Volume

10,048,011 shs

Market Capitalization

$32.64 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of BioTelemetry?

The following Wall Street sell-side analysts have issued research reports on BioTelemetry in the last twelve months: Benchmark Co., Dawson James, and StockNews.com.
View the latest analyst ratings for BEAT.

What is the current price target for BioTelemetry?

0 Wall Street analysts have set twelve-month price targets for BioTelemetry in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for BioTelemetry in the next year.
View the latest price targets for BEAT.

What is the current consensus analyst rating for BioTelemetry?

BioTelemetry currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BEAT will outperform the market and that investors should add to their positions of BioTelemetry.
View the latest ratings for BEAT.

What other companies compete with BioTelemetry?

How do I contact BioTelemetry's investor relations team?

BioTelemetry's physical mailing address is 1000 CEDAR HOLLOW ROAD, MALVERN PA, 19355. The medical research company's listed phone number is 610-729-7000 and its investor relations email address is [email protected] The official website for BioTelemetry is www.gobio.com. Learn More about contacing BioTelemetry investor relations.